Literature DB >> 20461371

111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.

Emilio Bombardieri1, Valentina Ambrosini, Cumali Aktolun, Richard P Baum, Angelica Bishof-Delaloye, Silvana Del Vecchio, Lorenzo Maffioli, Luc Mortelmans, Wim Oyen, Giovanna Pepe, Arturo Chiti.   

Abstract

This document provides general information about somatostatin receptor scintigraphy with (111)In-pentetreotide. This guideline should not be regarded as the only approach to visualise tumours expressing somatostatin receptors or as exclusive of other nuclear medicine procedures useful to obtain comparable results. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of (111)In-pentetreotide scintigraphy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20461371     DOI： 10.1007/s00259-010-1473-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  34 in total

1.  Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.

Authors:  H R Balon; S J Goldsmith; B A Siegel; E B Silberstein; E P Krenning; O Lang; K J Donohoe
Journal:  J Nucl Med       Date:  2001-07       Impact factor: 10.057

2.  Radiological Protection in Biomedical Research. A report of Committee 3 adopted by the International Commission on Radiological Protection.

Authors: 
Journal:  Ann ICRP       Date:  1991

3.  Routine quality control recommendations for nuclear medicine instrumentation.

Authors:  Ellinor Busemann Sokole; Anna Płachcínska; Alan Britten; Maria Lyra Georgosopoulou; Wendy Tindale; Rigobert Klett
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03       Impact factor: 9.236

4.  Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.

Authors:  R Lebtahi; G Cadiot; N Delahaye; R Genin; D Daou; M C Peker; D Chosidow; M Faraggi; M Mignon; D Le Guludec
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

5.  Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.

Authors:  J E Westlin; E T Janson; H Arnberg; H Ahlström; K Oberg; S Nilsson
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

Review 6.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

7.  SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors.

Authors:  O Schillaci; F Scopinaro; S Angeletti; R Tavolaro; R Danieli; B Annibale; G Gualdi; G Delle Fave
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

8.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.

Authors:  A Chiti; S Fanti; G Savelli; A Romeo; B Bellanova; M Rodari; B J van Graafeiland; N Monetti; E Bombardieri
Journal:  Eur J Nucl Med       Date:  1998-10

9.  Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007.

Authors: 
Journal:  Ann ICRP       Date:  2008

10.  Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.

Authors:  K M Kälkner; E T Janson; S Nilsson; S Carlsson; K Oberg; J E Westlin
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701
View more
  42 in total

1.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

Review 2.  SPECT/CT and tumour imaging.

Authors:  Gad Abikhzer; Zohar Keidar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-29       Impact factor: 9.236

3.  Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis.

Authors:  Paco E Bravo; Amitoj Singh; Marcelo F Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2018-11-02       Impact factor: 5.952

Review 4.  Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.

Authors:  Sander M Bison; Mark W Konijnenberg; Marleen Melis; Stefan E Pool; Monique R Bernsen; Jaap J M Teunissen; Dik J Kwekkeboom; Marion de Jong
Journal:  Clin Transl Imaging       Date:  2014-03-05

Review 5.  Somatostatin receptor expression in non-classical locations - clinical relevance?

Authors:  Eldrin Bhanat; Christian A Koch; Rinkuben Parmar; Vishnu Garla; Vani Vijayakumar
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

6.  A potentially misleading finding at somatostatin receptor scintigraphy: focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions.

Authors:  F Minutoli; A Herberg; A Sindoni; D Cardile; M Cucinotta; S Baldari
Journal:  J Endocrinol Invest       Date:  2012-07       Impact factor: 4.256

Review 7.  Somatostatin receptor SPECT.

Authors:  Giovanna Pepe; Roy Moncayo; Emilio Bombardieri; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 8.  Neuroendocrine tumours: the role of imaging for diagnosis and therapy.

Authors:  Martijn van Essen; Anders Sundin; Eric P Krenning; Dik J Kwekkeboom
Journal:  Nat Rev Endocrinol       Date:  2013-12-10       Impact factor: 43.330

9.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

10.  Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.

Authors:  Stefano Severi; Oriana Nanni; Lisa Bodei; Maddalena Sansovini; Annarita Ianniello; Stefania Nicoletti; Emanuela Scarpi; Federica Matteucci; Laura Gilardi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-27       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.